about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Take­da touts a land­mark head-to-head PhI­I­Ib win over Hu­mi­ra; Al­ler­gan's oral CGRP is now un­der FDA re­view

7 years ago
News Briefing

Pfiz­er takes its op­tion in An­Tol­Rx deal; Se­cu­ra Bio scores ac­cess to $145M for can­cer drug launch­es

7 years ago
News Briefing

The drug pric­ing de­bate in Amer­i­ca reach­es a boil­ing point at #JPM19

7 years ago
Pharma

Kalei­do prices $75M IPO well be­low range; Sage rais­es $575M ahead of FDA de­ci­sion

7 years ago
News Briefing

Days af­ter In­di­v­ior launch­es au­tho­rized Sub­ox­one gener­ic, My­lan of­fers its copy­cat; In crowd­ed CGRP mar­ket, Alder ...

7 years ago
News Briefing

Mer­ck goes in deep­er with Keytru­da/Lyn­parza com­bo; PureTech un­veils stem cell ther­a­py start­up

7 years ago
News Briefing

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

7 years ago
News Briefing

Equi­l­li­um's im­muno-in­flam­ma­to­ry drug wins FDA's or­phan drug sta­tus; Van­da sues FDA for man­dat­ing lengthy dog study

7 years ago
News Briefing

Am­gen, Sanofi back a round for re­al-world ev­i­dence plat­form tech; Dai­ichi Sanky­o's pex­i­dar­tinib se­cures speedy FDA ...

7 years ago
News Briefing

Halozyme scores $30M in cash for its lat­est al­liance; Bernie Sanders takes aim at $375,000 rare dis­ease drug

7 years ago
News Briefing

FDA stiff-arms Aveo on ti­vo, again; Sunovion Parkin­son's drug re­ject­ed

7 years ago
News Briefing

Aldeyra bags PhI­II-ready eye drug in He­lio buy­out; Liq­uid biop­sy mak­er On­co­Cyte shares sky­rock­et on val­i­da­tion da­ta

7 years ago
News Briefing

Rit­ux­an copy­cat pass­es first piv­otal test for Am­gen, Al­ler­gan; Iron­wood and biotech spin­out name new boards

7 years ago
News Briefing

RNAi leader Al­ny­lam inks col­lab­o­ra­tion pact with start­up; GV's Rosana Kapeller joins Schrödinger board

7 years ago
News Briefing

The 2018 break­down on a chart-top­ping set of new drug ap­provals — and the 5 big things we learned from it

7 years ago
Special
Pharma

Tossed in a storm of con­tro­ver­sies, Pro­teosta­sis finds shel­ter in $100M cash Roche deal — shares surge

7 years ago
Pharma

Eu­ro­pean VC firm Kur­ma sets its sights on €150 mil­lion fund, its biggest ever

7 years ago
Financing

Plow­ing ahead af­ter its lat­est set­back, Ax­o­vant nabs two as­sets to beef up gene ther­a­py pipeline

7 years ago
R&D
Pharma

Un­der pres­sure, drug­mak­ers di­lute price hikes, but noth­ing is set in stone just yet — re­port

7 years ago
Pharma

My­lan claims win in Lan­tus patent bat­tle, but le­gal war with Sanofi is far from over

7 years ago
Pharma

Lil­ly, In­cyte's baric­i­tinib wins fast-track sta­tus for hard-to-treat lu­pus; Syn­thorx ham­mers out $150M+ IPO

7 years ago
News Briefing

Third Rock, Take­da-backed Am­bys ush­ers in ex-NGM Bio pres­i­dent Jeff Jonker as CEO

7 years ago
People

'Idea Man' Paul Allen leaves be­hind plan to un­scram­ble hu­man im­munol­o­gy

7 years ago
People

Art Krieg moves from CEO post to CSO at Check­mate; In­di­v­ior breathes sigh of re­lief af­ter court rul­ing

7 years ago
News Briefing
First page Previous page 18192021222324 Next page Last page
A service from the Financial Times